PRMT1 enhances oncogenic arginine methylation of NONO in colorectal cancer
Xin-Ke Yin, Yunlong Wang, Fei Wang, Wei-Xing Feng, Shao-Mei Bai, Wan-Wen Zhao, Li-Li Feng, Ming-Biao Wei, Cao-Litao Qin, Fang Wang, Zhi-Li Chen, Hong-Jun Yi, Yan Huang, Pei-Yi Xie, Tae‐Wan Kim, Ying‐Nai Wang, Jun-Wei Hou, Chia‐Wei Li, Quentin Liu, Xinjuan Fan, Mien‐Chie Hung, Xiang‐Bo Wan
Abstract
Arginine methylation is an important posttranslational modification catalyzed by protein arginine methyltransferases (PRMTs). However, the role of PRMTs in colorectal cancer (CRC) progression is not well understood. Here we report that non-POU domain-containing octamer-binding protein (NONO) is overexpressed in CRC tissue and is a potential marker for poor prognosis in CRC patients. NONO silencing resulted in decreased proliferation, migration, and invasion of CRC cells, whereas overexpression had the opposite effect. In a xenograft model, tumors derived from NONO-deficient CRC cells were smaller than those derived from wild-type (WT) cells, and PRMT1 inhibition blocked CRC xenograft progression. A mass spectrometry analysis indicated that NONO is a substrate of PRMT1. R251 of NONO was asymmetrically dimethylated by PRMT1 in vitro and in vivo. Compared to NONO WT cells, NONO R251K mutant-expressing CRC cells showed reduced proliferation, migration, and invasion, and PRMT1 knockdown or pharmacological inhibition abrogated the malignant phenotype associated with NONO asymmetric dimethylation in both KRAS WT and mutant CRC cells. Compared to adjacent normal tissue, PRMT1 was highly expressed in the CRC zone in clinical specimens, which was correlated with poor overall survival in patients with locally advanced CRC. These results demonstrate that PRMT1-mediated methylation of NONO at R251 promotes CRC growth and metastasis, and suggest that PRMT1 inhibition may be an effective therapeutic strategy for CRC treatment regardless of KRAS mutation status.